<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936624</url>
  </required_header>
  <id_info>
    <org_study_id>SOTB07_AST_II_2008</org_study_id>
    <nct_id>NCT00936624</nct_id>
  </id_info>
  <brief_title>Dose Finding Trial to Assess the Efficacy and Safety of SOTB07 in Persistent Asthma</brief_title>
  <official_title>A 12 Week, Multi-center,Randomized, Double Blinded, Parallel Group, Placebo-controlled, 4-arm, Dose Finding Trial to Assess the Efficacy and Safety of SOTB07 in Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a dose finding trial to assess the efficacy and safety of SOTB07 in persistent
      asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 12 week, Multi-center, Randomized, Double blinded, Parallel group, Placebo-controlled,
      4-arm, Dose finding trial to Assess the Efficacy and Safety of SOTB07 in persistent asthma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% change from baseline for FEV1 at each visit</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>SOTB07 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SOTB07 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOTB07</intervention_name>
    <description>SOTB07 100mg</description>
    <arm_group_label>SOTB07 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOTB07</intervention_name>
    <description>SOTB07 200mg</description>
    <arm_group_label>SOTB07 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast</intervention_name>
    <description>montelukast 10mg po, bid, 12week</description>
    <arm_group_label>Montelukast 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or eligible female subjects aged 15 years or more

          2. A female is eligible if she is of:

               -  Non-child bearing potential (i.e., physiologically incapable of becoming
                  pregnant), including any female who is at least 2 year after post- menopausal

               -  Child bearing potential and agrees to the acceptable contraceptive methods used
                  consistently and correctly

               -  Negative pregnancy test at screening

          3. Non-smoker for at least 1 year, a pack history of ≤ 10 pack years

          4. Symptom of persistent asthma, as defined by the National Institute of Health (NIH)

          5. 50% ≤ FEV1 ≤ 85% predicted at screening visit (withholding inhaled, short acting
             ß-agonist for 6 hours)

          6. FEV1 reversibility ≥ 12% and 200 ml at 20-30 minutes after inhalation of a short
             acting ß-agonist (Salbutamol 2 puffs; 200㎍) at Visit 1 or within 6 months before Visit
             1

          7. Capable of withholding salbutamol use for ≥ 6 hours prior to clinic visits

          8. Appropriately signed and dated informed consent has been obtained

        Exclusion Criteria:

          1. Active upper or lower respiratory tract infection within 3 weeks before visit 1

          2. Emergency room treatment for asthma within 1 month or hospitalization for asthma
             within 3 months before visit 1

          3. Any evidence of infectious, oncologic, or other active pulmonary disease obtained by
             chest radiography within 12 months before visit 1

          4. Clinically significant, in the opinion of the investigator, hematological, liver,
             renal, heart, neurological disease, or other serious disease

          5. Hypersensitivity to any β2-agonist, sympathomimetic drug, leukotriene receptor
             antagonist or Sophora tonkinensis Radix Rhizoma

          6. Clinically significant and uncontrolled psychiatric disease or history of drug or
             alcohol abuse

          7. Inhaled, oral or parenteral corticosteroids within 4 weeks before visit 1

          8. Change of Immunotherapy within 6 months before visit 1

          9. Administration of the antiasthma agent within 1 week of visit 1

         10. Administration of any other medication which may affect the course of asthma, or
             interact with sympathomimetic amines

         11. Participation in study using an experimental medication within 1 month before visit 1

         12. Other ineligible subject in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sangheon Cho, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistent asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

